Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Talk to an Optune® user through the Buddy Program

If you or a loved one is considering or has recently started Optune, you may want to talk to someone who knows what Optune is like. The Optune Buddy Program connects you with users and/or their caregivers who have experience with Optune. They have been where you are now and they want to share what they've learned with you.

Here are some of our Optune users and their caregivers.

See real users share their experiences Meet Brian
See real users share their experiences Meet Susan
See real users share their experiences Meet Kathy
See real users share their experiences Meet Pat
See real users share their experiences Meet Brian “My perspective is that every extra day I get is another day to enjoy and try to do more with my friends and family!” - Brian, Optune Ambassador
See real users share their experiences Meet Susan “My husband [Brian] loves it when I shave his head, it feels good and he likes the attention. Also, as a caregiver, it makes me feel good that I can help with his treatment.” - Susan, Optune Ambassador Brian's caregiver
See real users share their experiences Meet Pat “I’ve taken the arrays off when I attended two family weddings. My caregiver [Kathy] attended the weddings too, and she came home with me afterwards to help me put the device back on.” - Pat, Optune Ambassador
See real users share their experiences Meet Kathy “I knew how upset she [Pat] was about shaving her head. It’s a hard thing for a woman to do, but she is a trooper. Now, she doesn’t really think about the fact that her head is shaved. And she has no issue going out! - Kathy, Optune Ambassador Pat's caregiver

You can request a call by filling out the form below or calling the toll-free registration line at 1-844-247-1636

()

nCompass complete support

Have a question about the device or transducer arrays? nCompass can help.

Email us

Daily life with Optune

What you need to know about incorporating Optune into your daily life.

Learn more
Find a Treatment Center

OPT-041.4-12


CONTACT AN OPTUNE EXPERT

What is Optune® approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

Who should not use Optune?

Optune is not for everyone. Talk to your doctor if you have:

Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?

Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.

What are the possible side effects of Optune?

Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

Talk to your doctor if you have any of these side effects or questions.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site and all images labeled as Optune users or caregivers depict actual patients and caregivers. All other depictions of patients, caregivers, and healthcare professionals are actor portrayals.


Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).